05.04.2026

Lineage Cell Therapeutics Reports 36-Month Data for OpRegen in Geographic Atrophy

Key Takeaways Three-year data show sustained visual acuity gains and retinal structural improvements following a single administration of OpRegen in GA patients Greater benefits were observed in patients with more extensive treatment coverage, with evidence of partial retinal restoration and photoreceptor recovery Ongoing phase 2a GAlette study aims to optimize delivery techniques and further evaluate the therapy’s potential to modify disease progression Lineage Cell Therapeutics announced new 36-month data from its phase 1/2a clinical study of RG6501 (OpRegen), an investigational retinal pigment epithelium (RPE) cell therapy for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The results were presented at the Foundation Fighting Blindness Retinal Therapeutics Innovation Summit 2026.